Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 6/20 | 0.63 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.50 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26264467 | 0.90 | SUCNR1 (0.78) | SUCNR1SCN9AP2RY12CTSA | |
| SCHEMBL26263580 | 0.88 | SUCNR1 (0.60) | SUCNR1SCN9AP2RY12CNR2CTSA | |
| SCHEMBL26263285 | 0.88 | SUCNR1 (0.81) | SUCNR1SCN9ACNR2CTSACNR1 | |
| SCHEMBL26263294 | 0.86 | SUCNR1 (0.60) | SUCNR1SCN9AP2RY12CNR2CTSA | |
| SCHEMBL26263279 | 0.85 | SUCNR1 (0.61) | SUCNR1SCN9AP2RY12CNR2CTSA | |
| SCHEMBL26263268 | 0.82 | SCN9A (0.60) | SUCNR1SCN9ACNR2CTSACNR1 | |
| SCHEMBL26264469 | 0.78 | SUCNR1 (0.71) | SUCNR1SCN9AP2RY12CNR2CTSA | |
| SCHEMBL26264461 | 0.77 | SUCNR1 (1.00) | SUCNR1SCN9ACTSA | |
| SCHEMBL22939952 | 0.76 | MAPT (0.47) | SUCNR1SCN9A | |
| SCHEMBL26264456 | 0.75 | SUCNR1 (0.75) | SUCNR1SCN9ACNR2CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | SUCNR1, SYNGR2, TSPO | SUCNR1 1/4885SCN9A 1628/4885P2RY12 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.